Conversely, CDK16 exhibited lower expression levels in five cancer types, specifically Kidney Renal Clear Cell Carcinoma (KIRC), Acute Myeloid Leukemia (LAML), Prostate Adenocarcinoma (PRAD), Testicular Germ Cell Tumor (TGCT), and Thyroid Carcinoma (THCA), as delineated in Figure 1A and Supplementary Table 1. The gene discussed is CDK16; the disease is prostate adenocarcinoma.